Get the Stockscreener App
2.10
1.45%
0.03
After Hours:
2.08
-0.02
-0.95%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.10, with a volume of 654.22K.
It is up +1.45% in the last 24 hours and up +1.45% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
654.22K
Relative Volume:
0.63
Market Cap:
$101.45M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.5217
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-2.78%
1M Performance:
+1.45%
6M Performance:
-23.64%
1Y Performance:
-78.06%
1-Day Range:
$2.04
$2.125
1-Week Range:
$2.04
$2.21
52-Week Range:
$1.15
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.10 | 104.35M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
SAVA STOCK ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Cassava Sciences, Inc. to Contact the Firm Today! - ACCESS Newswire
Cassava Sciences, Inc.(NasdaqCM:SAVA) dropped from Russell Small Cap Comp Growth Index - MarketScreener
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting - GlobeNewswire
Cassava Sciences reports simufilam reduced seizures in mouse model - Investing.com
Is Cassava Sciences, Inc. technically bullish or bearish? - MarketsMojo
Shareholders Filed a Lawsuit Against Cassava Sciences for Misleading Alzheimer’s Drug Claims - TradingView
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Sold by Cetera Investment Advisers - Defense World
BNP Paribas Financial Markets Buys 55,813 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Cassava Sciences, Inc. (NASDAQ:SAVA) Stake Lifted by Northern Trust Corp - Defense World
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
Cassava Sciences Holds 2025 Annual Meeting, Elects Directors - TipRanks
Transcript : Cassava Sciences, Inc.Shareholder/Analyst Call - marketscreener.com
Cassava Sciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationSAVA - ACCESS Newswire
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA)February 10, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Reports Q1 2025 Financials Results, Provides Business Update - GlobeNewswire
Cassava Sciences Shifts Focus to TSC-Related Epilepsy - TipRanks
Cassava Sciences (SAVA) Faces Financial Challenges Amid Strategic Shifts - GuruFocus
Invesco Ltd. Trims Stock Position in Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cassava Sciences (SAVA) Appoints New SVP of Neuroscience | SAVA Stock News - GuruFocus
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC - citybiz
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):